A randomized, controlled trial of an aerosolized vaccine against measles

New England Journal of Medicine

Volumn 372, Issue 16, 2015, Pages 1519-1529

  Low, N ^a   Bavdekar, A ^c   Jeyaseelan, L ^g   Hirvez, S ^f   Ramanathan, K ^g   Andrews, Nj ⁱ   Shaikh, N ^d   Jadi, R S ^d   Rajagopal, A ^g   Brown, K E ⁱ   Brown, David ⁱ   Fink, J B ^j   John, O ^h   Scott, Pippa ^a   Riveros Balta, A X ^b   Greco, M ^k   Dhere, R ^e   Kulkarni, P S ^e   Restrepo, A M H ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c KEM HOSPITAL   (India)

^d NATIONAL INSTITUTE OF VIROLOGY   (India)

^e Serum Institute of India   (India)

^f Shirdi Sai Baba Rural Hospital   (India)

^g CHRISTIAN MEDICAL COLLEGE   (India)

^h WHO Regional Office for South East Asia   (India)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

^j Aerogen Ltd   (Ireland)

^k NONE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; AEROSOL; VIRUS ANTIBODY;

AEROSOL; ANOREXIA; ARTICLE; COMMON COLD; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; IRRITABILITY; MALAISE; MALE; MEASLES; MEASLES VACCINATION; OPEN STUDY; PATHOLOGICAL CRYING; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; SEROCONVERSION; SHIVERING; SINGLE DRUG DOSE; TREATMENT OUTCOME; VIRUS NEUTRALIZATION; VOMITING; WHEEZING; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGY; INDIA; INHALATIONAL DRUG ADMINISTRATION; MEASLES VIRUS; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIBODIES, VIRAL; FEMALE; HUMANS; INDIA; INFANT; INJECTIONS, SUBCUTANEOUS; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS;

EID: 84928037305     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407417     Document Type: Article

References (30)

1. Global vaccine action plan 2011-2020. Geneva: World Health Organization, 2013 (http://www .who .int/ immunization/ global -vaccine-action-plan/ GVAP-doc-2011- 2020/ en).
2. Katz SL, Enders JF. Immunization of children with a live attenuated measles virus. AMA J Dis Child 1959; 98: 605-7.
3. Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012; 379: 2173-8.
4. Measles deaths reach record lows with fragile gains toward global elimination. Geneva: World Health Organization, 2014 (http://www .who .int/ mediacentre/ news/ notes/ 2014/ measles-20140206/ en/ index .html).
5. Omer SB, Hiremath GS, Halsey NA. Respiratory administration of measles vaccine. Lancet 2010; 375: 706-8.
6. Garrison LP Jr, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. J Infect Dis 2011; 204: Suppl 1: S124-S132.
7. The immunological basis for immunization series. Module 7: measles update 2009. Geneva: Department of Immunization, Vaccines and Biologicals, World Health Organization, 2009 (http:// whqlibdoc .who .int/ publications/ 2009/ 9789241597555-eng .pdf).
8. Fernández-de Castro J, Kumate-Rodríguez J, Sepúlveda J, Ramírez-Isunza JM, Valdespino-Gómez JL. Measles vaccination by the aerosol method in Mexico. Salud Publica Mex 1997; 39: 53-60. (In Spanish.)
9. Wong-Chew RM, Islas-Romero R, García-García Mde L, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to ninemonth- old Mexican children. Vaccine 2006; 24: 683-90.
10. Wong-Chew RM, Islas-Romero R, García-García Mde L, et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 2004; 189: 254-7.
11. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997; 25: 323-38.
12. Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. Hum Vaccin 2005; 1: 30-6.
13. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008; 26: 383-98.
14. Henao-Restrepo AM, Greco M, Laurie X, John O, Aguado T. Measles aerosol vaccine project. Procedia Vaccinol 2010; 2: 147-50.
15. Workbook for investigators. Geneva: World Health Organization Special Pro- gram for Research and Training in Tropical Diseases, 2002 (http://www .who .int/ tdr/ publications/ documents/ investigator .pdf ).
16. Handbook: good laboratory practice: quality practices for regulated non-clinical research and development. Geneva: World Health Organization Special Program for Research and Training in Tropical Diseases, 2001 (http://www .who .int/ tdr/ publications/ training-guideline-publications/ good -laboratory-practice-handbook-ver1/ en).
17. International Institute for Population Sciences (IIPS). District level household and facility survey (DLHS-3), 2007-08: India. Mumbai, India: IIPS, April 2010 (http:// www .rchiips .org/ pdf/ india-report-dlhs-3 .pdf).
18. World Health Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84: 349-60.
19. International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH). 2013 (http:// www .indepth-network .org/ Profiles/ vadu- hdss-2013 .pdf).
20. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virusspecific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 2008; 26: 6392-7.
21. Bonhoeffer J, Bentsi-Enchill A, Chen RT, et al. Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine 2009; 27: 2282-8.
22. Bose AS, Jafari H, Sosler S, et al. Case based measles surveillance in Pune: evidence to guide current and future measles control and elimination efforts in India. PLoS One 2014; 9(10): e108786.
23. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-90.
24. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681-94.
25. Wong-Chew RM, García-León ML, Espinosa-Torres Torrija B, et al. Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously. J Infect Dis 2011; 204: 426-32.
26. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353: 98-102.
27. Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 2004; 189: Suppl 1: S27-S35.
28. Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 2000; 355: 798-803.
29. Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 2007; 25: 4170-4.
30. Beutels P, Gay NJ. Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country. Epidemiol Infect 2003; 130: 273-83.